Real world data from over ten years of natalizumab use shows the drug continues to be effective in relapsing-remitting MS and without any new or unexpected safety signals. The Tysabri Observational Program (TOP), which last reported after five years of data, has now reported on more than 6,000 patients from 17 countries including Australia. Led ...
TOP trial shows natalizumab outcomes after 10 years: Prof Helmut Butzkueven
By Mardi Chapman
1 Apr 2020